Positive Phase 3 Trial Results Set Up Lilly’s Mounjaro for Potential Approval This Year

Eli Lilly just wrapped up its SURMOUNT-2 phase 3 trial for Mounjaro (tirzepatide), with results showing that the drug successfully helped patients with Type 2 diabetes lose weight. Patients taking a 15 mg maintenance dose lost 15.7% of their body weight while those taking a lower dose lost 13.4%, significantly higher than the 3.2% lost by those given placebo.

According to Angus Liu, “The analysis only considered efficacy while patients were on treatment, but a separate analysis looked at those who discontinued treatment. In that analysis, the drug was associated with an average body weight reduction of 14.7% for the 15-mg dose and 12.8% for the 10-mg dose, versus 3.2% for placebo.”

To read more, click here.

(Source: Fierce Pharma, April 27^th, 2023)